PDCD1 and nonpapillary renal cell carcinoma: Immune checkpoint inhibitors (ICI) were introduced in clear cell renal cell carcinoma (ccRCC) as a second-line treatment in the metastatic setting (mccRCC) with the approval of nivolumab monotherapy, an antibody blocking the-programmed cell death protein-1 (PD-1) [1].